288 related articles for article (PubMed ID: 12823203)
1. TP53 mutations in malignant and premalignant Barrett's esophagus.
Dolan K; Walker SJ; Gosney J; Field JK; Sutton R
Dis Esophagus; 2003; 16(2):83-9. PubMed ID: 12823203
[TBL] [Abstract][Full Text] [Related]
2. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.
Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA
J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
4. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus.
Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK
Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431
[TBL] [Abstract][Full Text] [Related]
5. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
6. TP53 gene mutations are rare in nondysplastic Barrett's esophagus.
Novotna K; Trkova M; Pazdro A; Smejkal M; Soukupova A; Kodetova D; Smejkal P; Sedlacek Z
Dig Dis Sci; 2006 Jan; 51(1):110-3. PubMed ID: 16416221
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer.
Casson AG; Manolopoulos B; Troster M; Kerkvliet N; O'Malley F; Inculet R; Finley R; Roth JA
Am J Surg; 1994 Jan; 167(1):52-7. PubMed ID: 8311140
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.
Dolan K; Morris AI; Gosney JR; Field JK; Sutton R
J Gastroenterol Hepatol; 2003 Jun; 18(6):683-9. PubMed ID: 12753151
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.
Del Portillo A; Lagana SM; Yao Y; Uehara T; Jhala N; Ganguly T; Nagy P; Gutierrez J; Luna A; Abrams J; Liu Y; Brand R; Sepulveda JL; Falk GW; Sepulveda AR
J Mol Diagn; 2015 Jul; 17(4):412-9. PubMed ID: 26068095
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
[TBL] [Abstract][Full Text] [Related]
11. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus.
Hamelin R; Fléjou JF; Muzeau F; Potet F; Laurent-Puig P; Fékété F; Thomas G
Gastroenterology; 1994 Oct; 107(4):1012-8. PubMed ID: 7523212
[TBL] [Abstract][Full Text] [Related]
12. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
[TBL] [Abstract][Full Text] [Related]
13. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.
González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E
J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671
[TBL] [Abstract][Full Text] [Related]
14. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
[TBL] [Abstract][Full Text] [Related]
15. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.
Audrézet MP; Robaszkiewicz M; Mercier B; Nousbaum JB; Hardy E; Bail JP; Volant A; Lozac'h P; Gouérou H; Férec C
Hum Mutat; 1996; 7(2):109-13. PubMed ID: 8829627
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus.
Li X; Paulson TG; Galipeau PC; Sanchez CA; Liu K; Kuhner MK; Maley CC; Self SG; Vaughan TL; Reid BJ; Blount PL
Cancer Prev Res (Phila); 2015 Sep; 8(9):845-56. PubMed ID: 26130253
[TBL] [Abstract][Full Text] [Related]
18. Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma.
Moore JH; Lesser EJ; Erdody DH; Natale RB; Orringer MB; Beer DG
Int J Cancer; 1994 Feb; 56(4):487-93. PubMed ID: 7906678
[TBL] [Abstract][Full Text] [Related]
19. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus.
Incarbone R; Bonavina L; Saino G; Bona D; Peracchia A
Surg Endosc; 2002 Feb; 16(2):263-6. PubMed ID: 11967675
[TBL] [Abstract][Full Text] [Related]
20. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus.
Guillem P; Billeret V; Buisine MP; Flejou JF; Lecomte-Houcke M; Degand P; Aubert JP; Triboulet JP; Porchet N
Int J Cancer; 2000 Dec; 88(6):856-61. PubMed ID: 11093805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
